Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Qianfoshan Hospital is the lead sponsor of 32 current clinical trials in our China register. 19 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Dexmedetomidine, Adebelizumab and Almonertinib. The most-studied condition is ABPA.

ClinicalTrials.gov trials by status

Recruiting1959%
Not yet open722%
Active, closed413%
By invitation26%

Trials by phase

Observational1650%
Not applicable722%
Phase 139%
Phase 426%
Phase 226%
Phase 313%
Phase 1/213%

Clinical trials sponsored by Qianfoshan Hospital

32 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Patient's Whole Process Follow-up Management(HOPE-1) NCT05339568 · ClinicalTrials.gov ↗ · Locally Advanced Non-Small Cell Lung Cancer, Metastatic NSCLC	Observational	Recruiting	2022-05	China
ML-Based ABPA Recurrence Prediction and Clinical Utility NCT07714863 · ClinicalTrials.gov ↗ · ABPA, Allergic Bronchopulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis (ABPA)	Observational	Recruiting	2021-01	China
Effect of Different Administration Routes of Dexmedetomidine Combined with Ultrasound-Guided Fascia Iliaca Block on Emergence Agitation After Hip Replacement Surgery NCT06614010 · ClinicalTrials.gov ↗ · Dexmedetomidine, Fascia Iliaca Block Drug: Dexmedetomidine	Phase 1	Recruiting	2023-02	China
Efficacy and Safety of Long-term Oral Staphylococcus Albicans Tablets in Patients With Bronchiectasis NCT05407792 · ClinicalTrials.gov ↗ · Bronchiectasis	Not applicable	Recruiting	2022-06	China
Efficacy and Safety of Triple-targeted Drug Therapy in Treatment-naive Patients With Non-low-risk PAH: A Real-world, Multicenter Study NCT06753981 · ClinicalTrials.gov ↗ · Arterial Pulmonary Hypertension (PAH)	Observational	Recruiting	2024-12	China
Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis NCT07530770 · ClinicalTrials.gov ↗ · Allergic Bronchopulmonary Aspergillosis, Severe Asthma, ABPA Drug: Benralizumab	Observational	Recruiting	2025-09	China
Almonertinib Combined With Anlotinib as First-line Treatment for Advanced Non-small Cell Lung Cance NCT06043973 · ClinicalTrials.gov ↗ · Advanced Non-small Cell Lung Cancer Drugs: Almonertinib, Anlotinib	Phase 3	Recruiting	2023-09	China
A Study of the Efficacy and Safety of Bronchoscopic Airway Clearance and Amphotericin B Spraying in Patients With ABPA NCT07362667 · ClinicalTrials.gov ↗ · ABPA, Allergic Bronchopulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis (ABPA)	Observational	Recruiting	2026-01	China
Pathogenesis and Inflammatory Phenotype of Allergic Bronchopulmonary Aspergillosis NCT07040332 · ClinicalTrials.gov ↗ · Allergic Bronchopulmonary Aspergillosis (ABPA)	Observational	Recruiting	2025-05	China
A Multicenter Prospective Study of Risk Factors in Progressive Pulmonary Fibrosis NCT05895409 · ClinicalTrials.gov ↗ · Interstitial Lung Disease	Observational	Recruiting	2023-07	China
Multi-Omics Inflammatory Phenotype for ABPA Recurrence Risk Prediction NCT07611838 · ClinicalTrials.gov ↗ · Allergic Bronchopulmonary Aspergillosis (ABPA), Machine Learning, Multi-omics	Observational	Recruiting	2021-01	China
Novel Biomarkers of Hypoxia and Metabolism in Clear Cell Renal Cell Carcinoma NCT05214885 · ClinicalTrials.gov ↗ · Clear Cell Renal Cell Carcinoma	Observational	Recruiting	2022-02	China
Nalbuphine Timing Effects on Hemodynamics and Analgesia in Elderly Patients NCT07271849 · ClinicalTrials.gov ↗ · Postoperative Pain, Acute, Hemodynamics, Total Knee Arthroplasty (TKA)	Phase 4	Recruiting	2025-10	China
Study on Topping-off Technique for Treating LDD NCT06650046 · ClinicalTrials.gov ↗ · Lumbar Degenerative Disease	Not applicable	Recruiting	2024-10	China
A Cohort Study of the Efficacy and Safety of Biologics in Patients With ABPA NCT07362693 · ClinicalTrials.gov ↗ · ABPA, Biologics, Allergic Bronchopulmonary Aspergillosis (ABPA)	Observational	Recruiting	2025-01	China
Mepilex Lite Dressings for the Treatment of Acute Radiation Dermatitis of Anal Canal Skin NCT06837831 · ClinicalTrials.gov ↗ · Rectal Cancer, Radiotherapy, Anal Pain, Acute Radiation Dermatitis	Not applicable	Recruiting	2026-02	China
Adebelizumab Combined With Chemotherapy and Radiotherapy Treat ES-SCLC NCT06125041 · ClinicalTrials.gov ↗ · Extensive Small Cell Lung Cancer Drugs: Adebelizumab, Carboplatin, Concurrent Radiotherapy	Phase 2	Recruiting	2023-10	China
Fungal Status and Prognosis in ABPA NCT07690345 · ClinicalTrials.gov ↗ · ABPA, Allergic Bronchopulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis (ABPA)	Observational	Recruiting	2025-07	China
Remimazolam Infusion in Kidney Transplant Patients: A Multicenter Study NCT07045467 · ClinicalTrials.gov ↗ · Chronic Kidney Diseases, Renal Transplantation Drug: Remimazolam Besylate	Phase 1	Recruiting	2025-07	China
ZR001 Chemogenetics Gene Therapy Study in Patients With Parkinson's Disease NCT07718659 · ClinicalTrials.gov ↗ · Parkinson's Disease (PD), Parkinsonian Disorders	Phase 1	Not yet open	2026-12	China
Effect of Opioid-free Anaesthesia on Postoperative Delirium in Elderly Patients Undergoing Gastrointestinal Surgery NCT06958393 · ClinicalTrials.gov ↗ · Delirium - Postoperative, Opioid-Free Anaesthesia Drugs: Dexmedetomidine, Esketamine, Esmolol	Phase 4	Not yet open	2025-05	China
Real-World Effectiveness of Tezepelumab in Allergic Bronchopulmonary Aspergillosis NCT07757841 · ClinicalTrials.gov ↗ · Allergic Bronchopulmonary Aspergillosis, Severe Asthma, ABPA Drug: Tezepelumab	Not applicable	Not yet open	2026-09	China
Real-World Effectiveness of Depemokimab in Allergic Bronchopulmonary Aspergillosis With Severe Eosinophilic Asthma NCT07828327 · ClinicalTrials.gov ↗ · Allergic Bronchopulmonary Aspergillosis, ABPA, Severe Eosinophilic Asthma Drug: Depemokimab	Not applicable	Not yet open	2026-11	China
TAS-102 Plus Radiotherapy in Elderly ESCC NCT07196345 · ClinicalTrials.gov ↗ · ESCC, TAS 102, Radiotherapy Drug: Trifluridine/Tipiracil	Phase 1/2	Not yet open	2025-09	China
QL1706 Plus Bevacizumab for Unresectable or Metastatic MSI-H/dMMR CRC NCT07009145 · ClinicalTrials.gov ↗ · Unresectable Colorectal Cancer, Metastatic Colorectal Cancer (CRC), MSI-H/dMMR Colorectal Cancer Drugs: Bevacizumab, Iparomlimab and Tuvonralimab	Phase 2	Not yet open	2025-06	China
Sedation of Remazolam Combined With Afentanil in Non-intubated Thoracoscopic Pulmonary Surgery NCT06810843 · ClinicalTrials.gov ↗ · Pulmonary Nodule Cm Drug: Propofol	Not applicable	Not yet open	2025-12	China
The Study of INTRA Spine Non Fusion Technique in the Treatment of Lumbar Degenerative Disease NCT06075966 · Lumbar Degenerative Disease	Not applicable	By invitation	2020-01	China
Efficacy and Safety of Sintilimab Combined with Platinum-containing Double-agent Chemotherapy in First-line Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer in Elderly Patients NCT06883136 · ClinicalTrials.gov ↗ · Non-Small Cell Lung Cancer Drugs: Gemcitabine, Sintilimab	Observational	By invitation	2025-03	China
Deep Learning Model and Risk Factors for Tacrolimus-related Acute Kidney Injury NCT06596798 · ClinicalTrials.gov ↗ · AKI	Observational	Active, closed	2024-09	China
Research on the Risk Warning Model and Prevention Strategies for Acute Kidney Injury Associated With Cyclosporine Based on Explainable Deep Neural Networks and Therapeutic Drug Monitoring NCT06596811 · ClinicalTrials.gov ↗ · AKI, Therapeutic Drug Monitoring (TDM)	Observational	Active, closed	2024-09	China
Effectiveness, Safety, and Economic Evaluation of Goserelin Microspheres for Injection and Goserelin Sustained-Release Implants in Prostate Cancer Patients: A Real-World Study NCT06929884 · ClinicalTrials.gov ↗ · Prostate Cancers	Observational	Active, closed	2020-04	China
A Study of the Clinical Benefit of Tobramycin Inhalation Solution NCT06106789 · ClinicalTrials.gov ↗ · Bronchiectasis, Cystic Fibrosis, Lung Infection	Observational	Active, closed	2023-04	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Qianfoshan Hospital trials

21 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Conditions in Qianfoshan Hospital trials

50 conditions

ABPA7Allergic Bronchopulmonary Aspergillosis6Allergic Bronchopulmonary Aspergillosis (ABPA)6Lumbar Degenerative Disease2AKI2Bronchiectasis2Severe Asthma2Parkinson's Disease (PD)1Parkinsonian Disorders1Locally Advanced Non-Small Cell Lung Cancer1Metastatic NSCLC1Acute Exacerbation1Dexmedetomidine1Fascia Iliaca Block1Therapeutic Drug Monitoring (TDM)1Arterial Pulmonary Hypertension (PAH)1Advanced Non-small Cell Lung Cancer1 Delirium - Postoperative1Opioid-Free Anaesthesia1Airway Clearance1Prostate Cancers1Interstitial Lung Disease1Machine Learning1Multi-omics1

By trial register

Register	Trials	Recruiting
Clinical trials in China	32	19

A trial with sites in more than one country appears in each of those registers.

Questions about Qianfoshan Hospital trials

How many clinical trials does Qianfoshan Hospital sponsor?

Qianfoshan Hospital is the lead sponsor of 32 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Qianfoshan Hospital trials recruiting?

Yes. 19 of its 32 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Qianfoshan Hospital testing?

Its current trials name 21 drugs and biologicals as interventions. The most frequent are Dexmedetomidine (2), Adebelizumab (1), Almonertinib (1), Anlotinib (1) and Benralizumab (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Qianfoshan Hospital clinical trials